THOROFARE, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers
Bio” or the "Company"), a developer of rapid health information technologies, announces that, on May 30, 2018, the Listing
Qualifications Department of the Nasdaq Stock Market ("Nasdaq") granted the Company a 180-day extension to meet the requirement of
a minimum $1.00 per share closing bid price of its common stock for 10 consecutive business days (the "Bid Price Requirement") for
continued inclusion on the Nasdaq Capital Market.
As previously disclosed, the Company received notice from Nasdaq on November 28, 2017, that it was not in
compliance with the Bid Price Requirements for its common stock. Per Nasdaq rules, the Company was afforded an initial 180 calendar
days to regain compliance with the Bid Price Requirement. The Company provided a written notice of its intention to cure the
deficiency during the second 180 calendar day compliance period by effecting a reverse stock split, if necessary.
Following a review, Nasdaq determined that the Company was eligible for an additional 180 calendar days to
regain compliance with the Bid Price Requirement. If at any time during the second 180 calendar day period the closing bid price of
the Company’s common stock, for the required minimum 10 consecutive business day period, meets the Bid Price Requirement and
provided that the Company meets the continued listing requirement for the market value of publicly held shares and all other
initial listing standards, Nasdaq will provide the Company with written confirmation that it is compliant with the Bid Price
Requirement and this matter will be closed.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker
and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies.
The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence.
The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings,
and to be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Note Regarding Forward-Looking Statements
Statements contained herein that are not based upon current or historical fact are forward-looking in nature and
constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities
that involve substantial risks and uncertainties. The forward-looking statements include statements or expectations regarding the
Company’s compliance with the Bid Price Requirement, the Company’s continued listing on Nasdaq, other risks detailed in the
Company's periodic reports filed with the Securities and Exchange Commission and other future events. Such statements may
include, without limitation, statements with respect to the Company’s plans, compliance with the requirements of various regulatory
agencies, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,”
“will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar
expressions, as they relate to the Company, its subsidiaries, or its management. These statements are based upon the current
beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those
detailed in the Company’s filings with the Securities and Exchange Commission. Actual results, performance, prospects, and
opportunities to may differ materially from those set forth in, or implied by, the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of
which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by applicable law.
For more information: Akers Biosciences, Inc. John J. Gormally, Chief Executive Officer Tel. +1 856 848 8698 Vigo Communications (Global Public Relations) Ben Simons / Fiona Henson Tel. +44 (0)20 7830 9704 Email: akers@vigocomms.com